PF614-MPAR
Management of severe pain with overdose protection
Phase 2Active
Key Facts
Indication
Management of severe pain with overdose protection
Phase
Phase 2
Status
Active
Company
About Ensysce Biosciences
Ensysce Biosciences is developing transformative, prodrug-based technologies to address the prescription opioid epidemic by preventing both abuse and overdose. Its core platforms, TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance), represent a paradigm shift from physical barrier formulations to intrinsic chemical control of drug activation. The company has achieved significant regulatory momentum with Fast Track and Breakthrough Therapy designations for its lead opioid candidates and is advancing clinical trials. Ensysce's strategy is to create safer pain therapies and potentially apply its chemistry to other drug classes with high abuse potential.
View full company profile